High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study.


Autoria(s): Rodondi N.; Darioli R.; Ramelet A.A.; Hohl D.; Lenain V.; Perdrix J.; Wietlisbach V.; Riesen W.F.; Walther T.; Medinger L.; Nicod P.; Desvergne B.; Mooser V.
Data(s)

2002

Resumo

BACKGROUND: Administration of 13-cis retinoic acid (isotretinoin) for acne is occasionally accompanied by hyperlipidemia. It is not known why some persons develop this side effect. OBJECTIVE: To determine whether isotretinoin triggers a familial susceptibility to hyperlipidemia and the metabolic syndrome. DESIGN: Cross-sectional comparison. SETTING: University hospital in Lausanne, Switzerland. PARTICIPANTS: 102 persons in whom triglyceride levels increased at least 1.0 mmol/L (> or =89 mg/dL) (hyperresponders) and 100 persons in whom triglyceride levels changed 0.1 mmol/L (< or =9 mg/dL) or less (nonresponders) during isotretinoin therapy for acne. Parents of 71 hyperresponders and 60 nonresponders were also evaluated. MEASUREMENTS: Waist-to-hip ratio; fasting glucose, insulin, and lipid levels; and apoE genotype. RESULTS: Hyperresponders and nonresponders had similar pretreatment body weight and plasma lipid levels. When reevaluated approximately 4 years after completion of isotretinoin therapy, hyperresponders were more likely to have hypertriglyceridemia (triglyceride level > 2.0 mmol/L [>177 mg/dL]; odds ratio [OR], 4.8 [95% CI, 1.6 to 13.8]), hypercholesterolemia (cholesterol level > 6.5 mmol/L [>252 mg/dL]; OR, 9.1 [CI, 1.9 to 43]), truncal obesity (waist-to-hip ratio > 0.90 [OR, 11.0 (CI, 2.0 to 59]), and hyperinsulinemia (insulin-glucose ratio > 7.2; OR, 3.0 [CI, 1.6 to 5.7]). In addition, more hyperresponders had at least one parent with hypertriglyceridemia (OR, 2.6 [CI, 1.2 to 5.7]) or a ratio of total to high-density lipoprotein cholesterol that exceeded 4.0 (OR, 3.5 [CI, 1.5 to 8.0]). Lipid response to isotretinoin was closely associated with the apoE gene. CONCLUSION: Persons who develop hypertriglyceridemia during isotretinoin therapy for acne, as well as their parents, are at increased risk for future hyperlipidemia and the metabolic syndrome.

Identificador

http://serval.unil.ch/?id=serval:BIB_DFC2A8A852C6

isbn:1539-3704 (Electronic)

pmid:11955026

isiid:000175125800003

Idioma(s)

en

Fonte

Annals of Internal Medicine, vol. 136, no. 8, pp. 582-589

Palavras-Chave #Acne Vulgaris/blood; Acne Vulgaris/drug therapy; Adolescent; Adult; Apolipoproteins E/genetics; Body Weight; Cross-Sectional Studies; Dermatologic Agents/adverse effects; Female; Genetic Predisposition to Disease; Genotype; Glucose Tolerance Test; Humans; Hyperlipidemias/chemically induced; Hyperlipidemias/genetics; Insulin/blood; Isotretinoin/adverse effects; Lipids/blood; Male; Metabolic Syndrome X/genetics; Middle Aged; Pharmacogenetics; Retrospective Studies; Risk Factors
Tipo

info:eu-repo/semantics/article

article